Human Immunodeficiency Virus and Leprosy Coinfection: Challenges in Resource-Limited Setups

Mycobacteria leprae(leprosy) and HIV coinfection are rare in Kenya. This is likely related to the low prevalence (1 per 10,000 of population) of leprosy. Because leprosy is no longer a public health challenge there is generally a low index of suspicion amongst clinicians for its diagnosis. Managemen...

Full description

Saved in:
Bibliographic Details
Main Authors: Charles M. Kwobah, Kara K. Wools-Kaloustian, Jane N. Gitau, Abraham M. Siika
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Case Reports in Medicine
Online Access:http://dx.doi.org/10.1155/2012/698513
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849403084989530112
author Charles M. Kwobah
Kara K. Wools-Kaloustian
Jane N. Gitau
Abraham M. Siika
author_facet Charles M. Kwobah
Kara K. Wools-Kaloustian
Jane N. Gitau
Abraham M. Siika
author_sort Charles M. Kwobah
collection DOAJ
description Mycobacteria leprae(leprosy) and HIV coinfection are rare in Kenya. This is likely related to the low prevalence (1 per 10,000 of population) of leprosy. Because leprosy is no longer a public health challenge there is generally a low index of suspicion amongst clinicians for its diagnosis. Management of a HIV-1-leprosy-coinfected individual in a resource-constrained setting is challenging. Some of these challenges include difficulties in establishing a diagnosis of leprosy; the high pill burden of cotreatment with both antileprosy and antiretroviral drugs (ARVs); medications’ side effects; drug interactions; scarcity of drug choices for both diseases. This challenge is more profound when managing a patient who requires second-line antiretroviral therapy (ART). We present an adult male patient coinfected with HIV and leprosy, who failed first-line antiretroviral therapy (ART) and required second-line treatment. Due to limited choices in antileprosy drugs available, the patient received monthly rifampicin and daily lopinavir-/ritonavir-based antileprosy and ART regimens, respectively. Six months into his cotreatment, he seemed to have adequate virological control. This case report highlights the challenges of managing such a patient.
format Article
id doaj-art-9872ca42525b4e0da6cca4e440b45e1b
institution Kabale University
issn 1687-9627
1687-9635
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Case Reports in Medicine
spelling doaj-art-9872ca42525b4e0da6cca4e440b45e1b2025-08-20T03:37:22ZengWileyCase Reports in Medicine1687-96271687-96352012-01-01201210.1155/2012/698513698513Human Immunodeficiency Virus and Leprosy Coinfection: Challenges in Resource-Limited SetupsCharles M. Kwobah0Kara K. Wools-Kaloustian1Jane N. Gitau2Abraham M. Siika3USAID-Academic Model Providing Access to Healthcare (AMPATH) partnership, P.O. Box 4606-30100, Eldoret, KenyaDivision of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN 46202-5124, USAUSAID-Academic Model Providing Access to Healthcare (AMPATH) partnership, P.O. Box 4606-30100, Eldoret, KenyaDepartment of Medicine, Moi University School of Medicine, P.O. Box 4606-30100, Eldoret, KenyaMycobacteria leprae(leprosy) and HIV coinfection are rare in Kenya. This is likely related to the low prevalence (1 per 10,000 of population) of leprosy. Because leprosy is no longer a public health challenge there is generally a low index of suspicion amongst clinicians for its diagnosis. Management of a HIV-1-leprosy-coinfected individual in a resource-constrained setting is challenging. Some of these challenges include difficulties in establishing a diagnosis of leprosy; the high pill burden of cotreatment with both antileprosy and antiretroviral drugs (ARVs); medications’ side effects; drug interactions; scarcity of drug choices for both diseases. This challenge is more profound when managing a patient who requires second-line antiretroviral therapy (ART). We present an adult male patient coinfected with HIV and leprosy, who failed first-line antiretroviral therapy (ART) and required second-line treatment. Due to limited choices in antileprosy drugs available, the patient received monthly rifampicin and daily lopinavir-/ritonavir-based antileprosy and ART regimens, respectively. Six months into his cotreatment, he seemed to have adequate virological control. This case report highlights the challenges of managing such a patient.http://dx.doi.org/10.1155/2012/698513
spellingShingle Charles M. Kwobah
Kara K. Wools-Kaloustian
Jane N. Gitau
Abraham M. Siika
Human Immunodeficiency Virus and Leprosy Coinfection: Challenges in Resource-Limited Setups
Case Reports in Medicine
title Human Immunodeficiency Virus and Leprosy Coinfection: Challenges in Resource-Limited Setups
title_full Human Immunodeficiency Virus and Leprosy Coinfection: Challenges in Resource-Limited Setups
title_fullStr Human Immunodeficiency Virus and Leprosy Coinfection: Challenges in Resource-Limited Setups
title_full_unstemmed Human Immunodeficiency Virus and Leprosy Coinfection: Challenges in Resource-Limited Setups
title_short Human Immunodeficiency Virus and Leprosy Coinfection: Challenges in Resource-Limited Setups
title_sort human immunodeficiency virus and leprosy coinfection challenges in resource limited setups
url http://dx.doi.org/10.1155/2012/698513
work_keys_str_mv AT charlesmkwobah humanimmunodeficiencyvirusandleprosycoinfectionchallengesinresourcelimitedsetups
AT karakwoolskaloustian humanimmunodeficiencyvirusandleprosycoinfectionchallengesinresourcelimitedsetups
AT janengitau humanimmunodeficiencyvirusandleprosycoinfectionchallengesinresourcelimitedsetups
AT abrahammsiika humanimmunodeficiencyvirusandleprosycoinfectionchallengesinresourcelimitedsetups